Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

Mar Esteban-Ortega
* ORCID logo ,
Martina Steiner
,
Cristina Andreu-Vázquez
,
Israel Thuissard-Vasallo
ORCID logo ,
Alvaro Diaz-Rato
,
Santiago Muñoz-Fernandez
ORCID logo
Version 1 : Received: 2 January 2024 / Approved: 3 January 2024 / Online: 3 January 2024 (09:44:07 CET)

A peer-reviewed article of this Preprint also exists.

Esteban-Ortega, M.; Steiner, M.; Andreu-Vázquez, C.; Thuissard-Vasallo, I.; Díaz-Rato, A.; Muñoz-Fernández, S. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis. J. Clin. Med. 2024, 13, 1402. Esteban-Ortega, M.; Steiner, M.; Andreu-Vázquez, C.; Thuissard-Vasallo, I.; Díaz-Rato, A.; Muñoz-Fernández, S. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis. J. Clin. Med. 2024, 13, 1402.

Abstract

To describe the characteristics of patients with uveitis associated with an immunologic or idio-pathic disease that requires immunosuppressive treatment and the response to such treatments in real clinical practice. Observational, descriptive, longitudinal, and retrospective study of a cohort of patients diagnosed with idiopathic uveitis or autoimmune disease-related uveitis. To assess the response to treatment we have evaluated the change in visual acuity and vitritis and the presence of macular edema. We included 356 patients. Twelve percent required treatment with systemic corticosteroids and 66 patients (18.5%) immunosuppressive/biological treatment, with metho-trexate being the most used (55%). Immunosuppressive drugs were used in 59 cases the least re-sponsive being mycophenolate mofetil. Ten patients of the 66 (15%) started treatment with bio-logics. Thirty-five patients (53%) needed to switch drugs due to a lack of response to the first one. There were no differences between different drugs in the resolution of vitritis and improvement of vision. The disappearance of macular edema was achieved in all patients treated with tocilizumab. The use of systemic corticosteroids and Immunosuppressive/biologics was necessary for a high number of patients with non-infectious uveitis. In our series tocilizumab was significantly more effective in the resolution of macular edema.

Keywords

uveitis; immunosuppressive therapy; biologic therapy; retrospective study; macular edema

Subject

Medicine and Pharmacology, Ophthalmology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.